Company news
Resverlogix Corp. (TSX:RVX) news
Resverlogix Corp. news releases on 6ix. Latest, Dec 16, 2009: Resverlogix Enters CAD $25 Million Standby Equity Agreement Term Sheet
Press releases — page 5
Resverlogix Enters CAD $25 Million Standby Equity Agreement Term Sheet
December 16, 2009
Resverlogix Commences Repurchase of Convertible Debenture Debt
November 18, 2009
Resverlogix Commends Dr. William Cochrane's Induction into the Canadian Medical Hall of Fame
October 26, 2009
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
October 16, 2009
Resverlogix Appoints A. Brad Cann as Chief Financial Officer
October 13, 2009
TSX Delisting Review - Resverlogix Corp. (RVX)
October 5, 2009
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
September 29, 2009
Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
September 25, 2009
Standard & Poor's annonce des modifications aux indices canadiens S&P/TSX
September 11, 2009
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
August 25, 2009
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed
May 19, 2009
Resverlogix Provides Quarterly Update
April 28, 2009
Resverlogix Closes CDN $24.25M Financing
April 15, 2009
Resverlogix Announces Subscriptions for its Equity Financing
April 6, 2009
Resverlogix Confirms a US $20 Million Equity Financing Plan
March 11, 2009
Resverlogix Board of Directors Update
November 26, 2008
RVX-208 Data Demonstrates Increase in Functional HDL Particles
November 10, 2008
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
November 10, 2008
Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
October 21, 2008
Resverlogix Announces Closing of Debt Redemption
October 17, 2008
Resverlogix Eliminates Sixty Percent of Remaining Debt
October 15, 2008
Resverlogix Issues a Management Statement
October 7, 2008
International Steering Committee for RVX-208 IVUS Trial Formed
October 7, 2008
ApoA-I Data Presented at European Society of Cardiology Congress
September 2, 2008
Phase 1b/2a Program Commences for RVX-208
August 25, 2008
Resverlogix Notice of Conference Call & Webcast
August 21, 2008
Jan Gray Joins Resverlogix Board of Directors
July 25, 2008
Resverlogix's Lead Drug Featured in Key Scientific Publication
July 18, 2008
Industry Leaders Select Resverlogix's RVX-208
July 9, 2008
Resverlogix to Collaborate with Cleveland Clinic
June 19, 2008
Key Primary Resverlogix Objective Obtained
June 18, 2008
/C O R R E C T I O N from Source -- Resverlogix Corp./
May 1, 2008
Dosing for RVX-208 Phase 1a Clinical Study Completed
April 22, 2008
Resverlogix Share Option Extension
April 21, 2008
Progress Report from RVX-208 Phase 1 Clinical Study
January 14, 2008
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
December 10, 2007
Resverlogix Honoured with World Economic Forum Technology Pioneer Award
November 29, 2007
Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
November 5, 2007
Resverlogix is Presenting at IAS HDL Workshop
October 11, 2007
Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
October 4, 2007